Certification adds CGH, ChIP-chip, DNA methylation, and gene-expression products to Ambry’s coverage.
Ambry Genetics has officially become a Certified Service Provider (CSP) for NimbleGen comparative genomic hybridization (CGH), chromatin immunoprecipiation-on-chip (ChIP-chip), DNA methylation, and gene expression. The firm, Roche NimbleGen’s first CSP in the U.S., is now certified on all Roche NimbleGen applications, the first CSP to attain this status.
A CAP-accredited, CLIA-certified commercial clinical laboratory, Ambry Genetics will process customer samples for copy number variation, DNA methylation analysis, gene-expression analysis, and DNA-protein interactions and chromatin structure. The company will use the complete NimbleGen Dual- and Single-Color microarray workflow, which includes the high-resolution MS 200 Microarray Scanner.
Ambry was initiated as a Roche NimbleGen CSP in the U.S. during September 2010. The company became a supplier of NimbleGen’s SeqCap EZ Exome sequence-capture technology, giving it the ability to offer target-enrichment services coupled with next-generation sequencing services for genetic research.
Earlier this month Ambry Genetics became the first authorized CSP in Ion Torrent’s new service provider program. Ion Torrent develops a sequencing system using semiconductor technology.